AUPH news & sentiment — Aurinia Pharmaceuticals Inc.

MAY 20·citybizMed

Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has successfully completed its tender offer for Kezar Life Sciences, with 80.24% of Kezar's outstanding shares tendered, exceeding the required majority threshold. The offer, supported by Information Agent Alliance Advisors, provided Kezar stockholders with $6.955 in cash per share plus a contingent value right. This transaction, valued at approximately $41.2 million, highlights Alliance Advisors' expertise in facilitating complex tender offers in the biopharmaceutical sector.

FEB 26·marketscreener.com

Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q4 Revenue $77.1M, vs. FactSet Est of $74.7M

Aurinia Pharmaceuticals Inc. (AUPH) reported Q4 revenue of $77.1 million, surpassing the FactSet consensus estimate of $74.7 million. This announcement follows their earlier report of Q4 EPS of $1.53. The company, focused on autoimmune diseases, is also anticipating to report full financial results for the three and twelve months ending December 31, 2025.

FEB 26·TradingView

Aurinia Pharmaceuticals Inc. SEC 10-K Report

Aurinia Pharmaceuticals Inc. has released its 2025 Form 10-K report, highlighting significant financial growth with total revenue up 20% to $283.1 million and a net income of $287.2 million. The report details the success of LUPKYNIS, ongoing product development for aritinercept, strategic restructuring, and capital management efforts, while also outlining challenges related to commercialization, regulation, and supply chain.

$AUPH

Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences

Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q4 Revenue $77.1M, vs. FactSet Est of $74.7M

Aurinia Pharmaceuticals Inc. SEC 10-K Report

News on $AUPH